“Evaluation of SARS‐CoV‐2 antibody titers and potency for CCP donation”, a WP4 Team commentary on Vox Sanguinis
“Evaluation of SARS‐CoV‐2 antibody titers and potency for convalescent plasma donation: a brief commentary” is the title of a Support-e WP4 team contribution that was published on Vox Sanguinis last december. This commentary (that you can read following this link) does not claim to provide evidence on how to select potent CCP, but does want to provide an opinion‐based discussion on how to investigate CCP potency.
WP4 Team is led by Sanquin (Netherlands) and vice-leaders are NHSBT (United Kingdom) and Belgian Red Cross. Its overall objective is to improve plasma potency assessment but also to facilitate anti-Sars-CoV-2 antibody testing, to obtain easy access and a cross-border standardization to of Plaque Reduction Neutralisation Test (PRNT) testing, to compare commercially available assays to PRNT and/or Microneutralisation (MN) and to characterise antibody content.
Support-E project is financed by the European Commission, and is implemented over a period of 2 years. It involves 12 partners from 8 European countries under the leadership of the European Blood Alliance (EBA), a not-for-profit association of blood establishments from 26 countries. Support-E will help evaluate the effectiveness of convalescent plasma by funding clinical trials and monitored access across Europe, and will draw up guidelines on how to make best use of this promising resource, using among other things the dedicated database created by the European Commission, in conjunction with EBA